Alefacept FDA Link

A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.

Also Known As:

Amevive; LFA-3 IgG(1) Fusion Protein; LFA-3 IgG1 Fusion Protein; LFA 3 IgG1 Fusion Protein

Carbohydrates: 22516
- Glycoconjugates: 1370
  - Glycoproteins: 25180
    - Membrane Glycoproteins: 2277
      - CD58 Antigens: 133
        Alefacept: 234
Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Glycoproteins: 25180
    - Membrane Glycoproteins: 2277
      - CD58 Antigens: 133
        Alefacept: 234
  - Blood Proteins: 12679
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Immunoglobulin Isotypes: 1094
        Immunoglobulin G: 59781
        Alefacept: 234
    - Immunoproteins: 43
      - Immunoglobulins: 30911
        Antibodies: 135587
        Immunoglobulin Isotypes: 1094
        Immunoglobulin G: 59781
        Alefacept: 234
  - Membrane Proteins: 10262
    - Membrane Glycoproteins: 2277
      - CD58 Antigens: 133
        Alefacept: 234
  - Globulins: 3119
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Immunoglobulin Isotypes: 1094
        Immunoglobulin G: 59781
        Alefacept: 234
  - Recombinant Proteins: 2811
    - Recombinant Fusion Proteins: 337
      - Alefacept: 234

Salman Bin Dayel Selected Research

Salman Bin Dayel Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure